| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 31/12/2025 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 31/12/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 18/06/2021 | |
Janis Buks
CHM | Chairman | - | 31/08/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04/08/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +7.19% | +2.67% | - | - | 148M | ||
| -0.18% | +1.00% | +15.36% | +77.38% | 48.41B | ||
| +2.79% | +1.95% | +61.90% | +112.57% | 34.99B | ||
| +1.72% | 0.00% | -4.65% | +35.25% | 11.62B | ||
| -0.40% | -3.03% | +14.18% | +80.68% | 11.47B | ||
| -0.37% | -0.19% | +36.83% | +136.73% | 8.99B | ||
| +1.58% | +0.47% | +48.92% | -5.74% | 6.88B | ||
| -0.77% | -3.48% | +13.66% | +32.01% | 6.62B | ||
| -0.80% | -2.21% | +1.95% | +177.32% | 6.43B | ||
| +1.60% | -15.49% | -29.66% | +8.47% | 5.75B | ||
| Average | +1.25% | -1.73% | +17.61% | +72.74% | 15.69B | |
| Weighted average by Cap. | +0.81% | -0.93% | +25.63% | +82.24% |
Employees
2,191
Sector
Pharmaceuticals
















